- Home
- AMRN vs DHF Comparison
AMRN vs DHF Comparison
Compare AMRN & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- DHF
- Stock Information
- Founded
- AMRN 1989
- DHF 1998
- Country
- AMRN Ireland
- DHF United States
- Employees
- AMRN N/A
- DHF N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- DHF Finance Companies
- Sector
- AMRN Health Care
- DHF Finance
- Exchange
- AMRN Nasdaq
- DHF Nasdaq
- Market Cap
- AMRN 216.0M
- DHF 172.4M
- IPO Year
- AMRN 1993
- DHF N/A
- Fundamental
- Price
- AMRN $15.80
- DHF $2.59
- Analyst Decision
- AMRN Strong Sell
- DHF
- Analyst Count
- AMRN 1
- DHF 0
- Target Price
- AMRN $12.00
- DHF N/A
- AVG Volume (30 Days)
- AMRN 172.9K
- DHF 451.1K
- Earning Date
- AMRN 07-30-2025
- DHF 01-01-0001
- Dividend Yield
- AMRN N/A
- DHF 7.65%
- EPS Growth
- AMRN N/A
- DHF N/A
- EPS
- AMRN N/A
- DHF N/A
- Revenue
- AMRN $214,112,000.00
- DHF N/A
- Revenue This Year
- AMRN N/A
- DHF N/A
- Revenue Next Year
- AMRN N/A
- DHF N/A
- P/E Ratio
- AMRN N/A
- DHF N/A
- Revenue Growth
- AMRN N/A
- DHF N/A
- 52 Week Low
- AMRN $7.08
- DHF $2.06
- 52 Week High
- AMRN $17.49
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- AMRN 60.01
- DHF 58.31
- Support Level
- AMRN $16.12
- DHF $2.56
- Resistance Level
- AMRN $17.49
- DHF $2.61
- Average True Range (ATR)
- AMRN 0.78
- DHF 0.03
- MACD
- AMRN -0.13
- DHF -0.00
- Stochastic Oscillator
- AMRN 34.42
- DHF 71.57
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.